Blenrep (belantamab mafodotin) plus BorDex showed statistically significant progression-free survival (PFS) benefit versus daratumumab plus BorDex
First-in-class AKT inhibitor has potential to reshape treatment for breast cancer patients
Approval based on results from the Phase 3 KEYNOTE-859 trial, which demonstrated significant improvement in overall survival in these patients versus chemotherapy alone
The NDA filing for deuruxolitinib with the U.S. FDA is based on two pivotal Phase III trials
Aim is to treat Dyslipidemia by inhibiting PCSK9 with a novel entity
The companies will work with investigators to share the results with the scientific community
The campaign for the digital film is being amplified across various digital media platforms such as YouTube, Facebook, Instagram, Twitter, and LinkedIn
Approval is for use in myelofibrosis patients with anaemia regardless of prior myelofibrosis therapy
Approval of this product under the PEPFAR program completes Strides’ qualification to all major markets and donor programs including Global Fund and South Africa
Patients Treated with ARIKAYCE plus macrolide-based background regimen had meaningfully larger improvements in QOL-B respiratory score
Subscribe To Our Newsletter & Stay Updated
